Ligand Pharmaceuticals Incorporated Stock News

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the completion of its acquisition of the core assets of Icagen’s North Carolina operations. As previously announced, the purchase price w

Advisor Group Inc. lessened its holdings in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 31.7% during the fourth quarter, according to the company in its most recent filing with the Securiti

The "Global Immune Checkpoint Inhibitors Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering.

Brokerages forecast that Ligand Pharmaceuticals Inc. (NASDAQ:LGND) will report sales of $26.05 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provide

Dublin, April 01, 2020 -- The "Global Immune Checkpoint Inhibitors Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering. Given the.

S&P Biotech ETF (XBI) slumped -20% year-to-date, in-line with the S&P 500, due to the unrelenting coronavirus pandemic,. Heavy exposure to small caps contribute

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) was the target of a large increase in short interest in the month of March. As of March 13th, there was short interest totalling 8,904,900 shares, an increase

Oxford Asset Management LLP bought a new position in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) during the 4th quarter, according to the company in its most recent Form 13F filing with the SE

Equities analysts expect Ligand Pharmaceuticals Inc. (NASDAQ:LGND) to post earnings of $0.61 per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Ligand Ph

AQR Capital Management LLC reduced its stake in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 20.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securit

Ligand Pharmaceuticals (NASDAQ:LGND) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, BidAskClub reports.

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) traded up 5.2% on Tuesday . The company traded as high as $76.20 and last traded at $74.18, 622,440 shares were traded during trading. An increase of 23% from

INTRODUCTIONThe process of drug development, beginning from the discovery of a pharmacological lead to its commercial launch, is estimated to take around 10-15 years, involving capital investments in

Ligand downgraded to Hold from Buy at Argus Argus LGND

Compugen (NASDAQ:CGEN) initiated with Buy rating and $16 (156% upside) price target at SunTrust. Shares up 9% premarket.Incyte (NASDAQ:INCY) resumed with Outperform rating at William Blair. Shares u